Antiretroviral Therapy, Highly Active
Research News and Information

Saturday, November 21, 2009

Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.

13 Nov 2009 BACKGROUND: The association between postnatal human immunodeficiency virus type 1 (HIV-1) transmission and maternal highly active antiretroviral therapy (HAART) after infant extended antiretroviral prophylaxis was assessed. METHODS: A follow-up ... Read more...

Gender differences in discontinuation of antiretroviral treatment regimens.

30 Oct 2009 BACKGROUND: Reported reasons for change or discontinuation of antiretroviral therapy ([delta]ART) include adverse events, intolerability, and nonadherence. Little is known how reasons for [delta]ART differ by gender. METHODS: In a retrospective ... Read more...

Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study.

30 Oct 2009 OBJECTIVE: The main aim of this study was to reduce breast-milk transmission of HIV-1 by treating HIV-1-infected women with highly active antiretroviral therapy (HAART) during breastfeeding. METHODS: Mitra Plus was an open-label, nonrandomized, ... Read more...

Latest indexed articles for 'Antiretroviral Therapy, Highly Active'

These are the very latest articles for this heading:

• HIV/AIDS and diabetes: minimizing risk, optimizing care. 29 Nov 2009
• Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy. 13 Nov 2009
• Strategic approaches to decrease breast milk transmission of HIV-1: the importance of small things. 13 Nov 2009
• Gender differences in discontinuation of antiretroviral treatment regimens. 30 Oct 2009
• Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study. 30 Oct 2009
• Prevention of breast milk transmission of HIV: the time is now. 30 Oct 2009
• The association between food insecurity and mortality among HIV-infected individuals on HAART. 30 Oct 2009
• Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study. 30 Oct 2009
• Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. 13 Oct 2009
• Interleukin-2 therapy in patients with HIV infection. 13 Oct 2009
• Strategies for Preventing HIV Transmission. 12 Oct 2009
• Strategies for preventing HIV transmission. 12 Oct 2009
• Cardiovascular risk assessment in antiretroviral-naïve HIV patients. 29 Sep 2009
• Long-term combination antiretroviral therapy is associated with the risk of coronary plaques in African Americans with HIV infection. 29 Sep 2009
• Early patterns of adherence in adolescents initiating highly active antiretroviral therapy predict long-term adherence, virologic, and immunologic control. 29 Sep 2009
• Antiretroviral adherence and pharmacokinetics: review of their roles in sustained virologic suppression. 29 Sep 2009
• Saquinavir, the pioneer antiretroviral protease inhibitor. 29 Sep 2009
• Gene copy number: learning to count past two. 29 Sep 2009
• Reply to: "Experimental aspects of copy number variant assays at CCL3L1". 29 Sep 2009
• Experimental aspects of copy number variant assays at CCL3L1. 29 Sep 2009

See a longer list of these articles.

Technical information about 'Antiretroviral Therapy, Highly Active'

Definition: Drug regimens, for patients with HIV INFECTIONS, that aggressively suppress HIV replication. The regimens usually involve administration of three or more different drugs including a protease inhibitor.

Descriptor UI: D023241

Alternative terms: Antiretroviral Therapy, Highly Active; Highly Active Antiretroviral Therapy; HAART;

Related Mesh Headings: Anti-HIV Agents;

Allowable Qualifiers: adverse effects; classification; economics; history; instrumentation; methods; mortality; nursing; psychology; standards; trends; utilization; veterinary; statistics & numerical data; contraindications; ethics;

Tree Number: E02.319.310.075;

History Note: 2001

Technical Notes: IM when general; NIM when with specific drugs